Contract research in discovery and lead optimization

February 2025 is “Heart Month”

February is Heart Month—a time to raise awareness about cardiovascular health.

At the heart of innovation, companies developing life-saving drugs show their commitment to the well-being of our communities. Because caring for hearts means caring for lives.

Contact us to see how we can combine your team’s experience with ours to accelerate your cardiovascular therapies.

Dedicated to scientific excellence since 1999, IPS Therapeutique (IPST) specializes in the preclinical evaluation of the efficacy and safety of new drugs using validated and highly predictive models

01 / Cardiovascular

Cardiovascular diseases

We leverage our world-class expertise on cardiovascular diseases, e.g., pulmonary arterial hypertension, myocardial infarction, hemorrhagic shock, acute kidney injury, to craft tailored protocols designed in collaboration with you.

02 / Inflammatory

Inflammatory disorders

We leverage our world-class expertise on inflammatory disorders, e.g., diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver fibrosis, cholestatic liver disease, to craft tailored protocols designed in collaboration with you.

03 / Respiratory

Respiratory diseases

We leverage our world-class expertise on respiratory diseases e.,g., chronic obstructive pulmonary disease, asthma, allergic rhinitis, pulmonary fibrosis, to craft tailored protocols designed in collaboration with you.

04 / Bleeding

Bleeding disorders

We leverage our world-class expertise on bleeding disorders, e.g., hemophilia, sickle cell anemia, immune thrombocytopenia, von Willebrand disease, to craft tailored protocols designed in collaboration with you.

Discover our featured white papers

Learn more about our ongoing scientific research.

Learn more

The benefits of inhalation models – A conversation with IPST’s Dan Salvail

by Dany Salvail Ph.D., Vice-President.

Published on May 1, 2022

A strategy to develop a cardiac anti-arrhythmic drug from scratch

by Dany Salvail Ph.D., Vice-President.

Published on June 19, 2023